M. Popkov et al., Inhibition of tumour growth and metastasis of human fibrosarcoma cells HT-1080 by monoclonal antibody BCD-F9, EUR J CANC, 37(18), 2001, pp. 2484-2492
BCD-F9 is it marine IgG(2a) monoclonal antibody (mAb) that recognises a con
formational epitope found on the surface of many human tumour cells. The ai
m of this study was to investigate the ability of BCD-F9 to recognise a var
iety of neoplastic cell lines and to test BCD-F9 in vivo for anticancer act
ivity in subcutaneous (s.c.) and metastatic tumour models. Intravenous (i.v
.) administration of BCD-F9 in CD-I nude mice xenografted s.c. with human H
T-1080 cells led to it significant inhibition of tumour growth. We demonstr
ated that BCD-F9 administrated i.v. significantly prolonged the life-span o
f CD-1 nude mice inoculated i.v. with the same tumour cell line that induce
s aggressive lung metastases in the untreated mice. We also investigated th
e antitumour activity of BCD-F9 in vitro in antibody-dependent cellular cyt
otoxicity (ADCC) and antibody-dependent complement-mediated cytotoxicity (A
DCMC) assays. The effector cell subpopulations were obtained by macrophage
stimulation (thioglycollate) or natural killer (NK) cell enrichment (negati
ve selection). BCD-F9 was found to be effective in mediating tumour cell ki
lling in vitro by ADCC and ADCMC mechanisms. These results suggest that the
mAb BCD-F9 can have it potential rise in immunotherapy for treatment of tu
mours of different origin. (C) 2001 Elsevier Science Ltd. All rights reserv
ed.